Library
of Slides and Posters
High
Rate of Virologic Success with Raltegravir (Isentress)
plus Etravirine (Intelence) and Darunavir/ritonavir (Prezista/r) in
Patients with Multi-drug-resistant HIV: Results of the TRIO Trial
Y Yazdanpanah
and others. AIDS 2008.
Pregabalin
vs Placebo for the Treatment of Painful HIV-associated Neuropathy
D
Simpson and others. AIDS 2008
Clinicians
Fail to Routinely Provide Reproductive Counseling to HIV-Infected
Women in the United States
D Averitt and others. AIDS 2008. Trough
Lopinavir Concentrations <1 ƒÊg/mL Are Not
Associated with Virologic Failure in Antiretroviral-Naive Patients Receiving a
Lopinavir/ritonavir-Based 3-Drug Regimen
Y
Chiu and others. AIDS 2008. Impact
of Gender on Response to Lopinavir/ritonavir (LPV/r)
Tablets Dosed QD or BID Administered with Tenofovir Disoproxil
Fumarate (TDF) and Emtricitabine (FTC) in Antiretroviral-naïve (ARV)
Subjects: Results from Study M05-730
B
Da Silva and others. AIDS 2008. Comparable
HIV-1 Viral Suppression and Immunologic Recovery of White and Non-White Antiretroviral-Naïve
Subjects Taking Lopinavir/ritonavir (LPV/r)
Tablets + Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC)
through 48 Weeks
B Da Silva and others. AIDS 2008.
Cost-effectiveness
of HLA-B*5701 Testing Prior to Initiation
of Abacavir Sulfate
R Farkouh and others. AIDS 2008.
Week-96
End of Trial Analysis of Antiretroviral-naïve Patients Randomized to the Lopinavir/ritonavir
Single Drug Arm in the MONARK Trial
J
Ghosen and others. AIDS 2008.
Physicians’
and HIV-patients’ Perceptions : Do They Agree?
R Landman and others. AIDS
2008.
A Comparison of the
Single Dose Bioavailability of a Ritonavir Tablet Formulation
Relative to the Ritonavir Soft Gelatin Capsule in Healthy Adult Subjects
J
Ng and others. AIDS 2008.
Predictors
of Persistence with Lopinavir/ritonavir (LPV/r)
Soft-Gelatin Capsule-Based Antiretroviral Regimens
R Rode and others. AIDS
2008.
TMC278
(rilpivirine), an Investigational Next-generation NNRTI, Demonstrates
Long-term Efficacy and Tolerability in ARV-naïve Patients: 96-week Results of
Study C204
M Santoscoy and others.
AIDS 2008.
Societal
Stigma of Pregnant HIV-Infected Women in the
United States
K Squires and others. AIDS 2008.
Health-Related
Quality of Life (HRQoL) Improvement in Antiretroviral (ARV) Naïve HIV-infected
Patients on Atazanavir or Lopinavir With Ritonavir
Regimens: Week 24 Results From the CASTLE Study
J
Su and others. AIDS 2008.
TMC278
(rilpivirine), an investigational next-generation NNRTI, demonstrates
long-term efficacy and tolerability in ARV-naïve patients: 96-week results of
study C204
M Santoscoy and others.
AIDS 2008.
Simplification
with Easier Emtricitabine and Tenofovir (SWEET):
Results of a 48 Week Analysis of Patients’ Perceptions of Treatment and Adherence
V
Cooper and others. AIDS 2008.
An
Open-Label Multicenter Study to Assess Efficacy, Tolerability and Adherence of
a Once Daily (OD) TDF-Containing HAART in
HIV-1-Infected Former IVDU-Patients Receiving Opiate Substitution - Final 48 Weeks
Analysis of 3OD
S. Esser and others. AIDS 2008.
Renal
Safety Profile of Tenofovir DF (TDF)-containing
vs. Thymidine Analog-containing Regimens Through 144 Weeks in Antiretroviral-naïve
Patients
J Gallant and others. AIDS 2008.
High
CD4 Count, Shorter Time to Viral Suppression and Association with NNRTI were Predictive
of Lower Risk of Virologic Rebound in Patients Receiving TDF-containing
Regimens
P Lorenzini and others. AIDS 2008.
The
Safety and Efficacy of Switching Stavudine to Tenofovir
DF in Combination with Lamivudine and Efavirenz
in HIV-1-Infected Patients: A Four-Year Follow-up
J Madruga and others.
AIDS 2008.
Black Race and Degree of Immunosuppression
Predict Rate of Proteinuria Before and After Combination Antiretroviral Treatment
(cART) in Italian HIV-infected Population
P Marconi and others. AIDS 2008.
Early
Improvement of Limb Fat Content in Patients Switching from AZT/3TC
to FTC/TDF (TVD): A Week 24 Interim Analysis of the RECOMB
Trial
E Martinez and others. AIDS 2008.
Efficacy
and Safety By Racial Group in ARV-Naïve Subjects Treated With Atazanavir/Ritonavir
or Lopinavir/Ritonavir: 48-Week Results for
the CASTLE Study (AI424138)
D McGratha
and others. AIDS 2008.
Gender-Based
Differences in ARV-Naïve Patients Treated with Boosted
Protease Inhibitors: Results From the CASTLE
Study (AI424138)
J Absalon and others. AIDS 2008.
Continuation
of BID boosted PI vs switch to once-daily ATV/RTV
for the management of lipodystrophy: 48-week primary analysis of the 96-week multicenter,
open-label, randomized, prospective REAL
Study
G Moyle and others. AIDS 2008
Health-Related
Quality of Life (HRQoL) Improvement in Antiretroviral (ARV) Naïve HIV-infected
Patients on Atazanavir or Lopinavir with Ritonavir
Regimens: Week 24 Results From the CASTLE Study
J
Su and others. AIDS 2008.
Tenofovir
Effect on Renal Function Factoring in Both MDRD-Calculated Glomerular Filtration
Rate (GFR) and Spot Urine Protein-to-Creatinine (UPC) Ratio
T Vanig and
others. AIDS 2008. Copyright GlaxoSmithKline. Used with permission, 2008.
HLA-B*5701
Screening Reduces Abacavir Hypersensitivity Reactions
(ABC HSR); Multiple Lines of Evidence to Establish a New Standard of Care
P
Wannamaker and others. AIDS 2008. Copyright GlaxoSmithKline. Used with permission,
2008.
Switching
to Fosamprenavir (FPV) Led to Similar Efficacy
and Safety in HIV-1-infected Subjects on their First PI Regimen: a Prospective,
Open-label, Multicenter, Randomized Trial (ESS100290)
B
Young and others. AIDS 2008. Copyright GlaxoSmithKline. Used with permission,
2008.
Is
Abacavir (ABC)-containing combination antiretroviral
therapy (CART) associated with myocardial infarction (MI)? No association identified
in pooled summary of 54 clinical trials
A
Cutrell and others. AIDS 2008. Copyright GlaxoSmithKline. Used with permission,
2008. Epzicom
QD vs Truvada QD, Both with Kaletra QD,
in ART-Naïve Patients: The HEAT Study 96 Weeks
Analysis Results
M Shaefer and others. AIDS 2008. Copyright GlaxoSmithKline.
Used with permission, 2008.
Similarity
in Efficacy and Safety of Abacavir/Lamivudine (ABC/3TC)
Compared to Tenofovir/Emtricitabine (TDF/FTC)
in Combination with QD Lopinavir/Ritonavir (LPV/r)
Over 96 Weeks in the HEAT Study
K Smith
and others. AIDS 2008. Copyright GlaxoSmithKline. Used with permission, 2008.
Abacavir/Lamivudine
(ABC/3TC) shows robust virologic responses in ART-naïve patients for
baseline (BL) viral loads (VL) of ? 100,000c/mL and <100,000c/mL by ACTG endpoint
K
Pappa and others. AIDS 2008. Copyright GlaxoSmithKline. Used with permission,
2008.
Cost-effectiveness
of HLA-B*5701 Testing Prior to Initiation
of Abacavir Sulfate
R Farkouh and others. AIDS 2008. Copyright GlaxoSmithKline.
Used with permission, 2008.
EPZICOM®
Virologic Response in ART-Naïve Patients with Baseline Viral Loads Above and Below
100,000c/mL Using the A5202 Endpoint
K Pappa and others. AIDS 2008. Copyright
GlaxoSmithKline. Used with permission, 2008.
Impact
of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected
Patients: Results of a Large Retrospective Database Study
M
Rawlings and others. AIDS 2008. Copyright GlaxoSmithKline. Used with permission,
2008.
| 
